Calls

Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-04-23 · generated 2026-07-17.

Latest call digest

Molina Healthcare, Inc., Q1 2026 Earnings Call, Apr 23, 2026 · 2026-04-23T12:00:00

Q1 2026 — reported April 23, 2026. Molina posted adjusted EPS of $2.35 on $10.2 billion of premium revenue, a 91.1% consolidated MCR and a 1.6% adjusted pretax margin. By segment, Medicaid ran a 92% MCR (January rate updates in line, trend modestly favorable), Medicare 89.8% (the newly converted FIDE/HIDE duals products off to a good start), and Marketplace 84% on 305,000 members after the deliberate exposure cut.

The prepared remarks and the Q&A diverged on one point: management called the quarter "solid" and modestly favorable, yet only reaffirmed full-year guidance of approximately $42 billion of premium and at least $5 of adjusted EPS rather than raising it. Full-year segment assumptions were left unchanged — Medicaid MCR 92.9% (4% rates, 5% trend), Medicare 94%, Marketplace 85.5%, G&A ~6.4%, with roughly two-thirds of earnings weighted to the first half and Florida CMS implementation weighing on the fourth quarter.

The Q&A was dominated by two pressures: whether the assumption of no further acuity shift is credible now that low-and-no-utilizers sit at the lowest level Molina has recorded, and why guidance was not raised. Management repeatedly invoked a "time tested" preference for two quarters of data after 2025's volatility. The one guidance change surfaced in Q&A: same-store Medicaid attrition was lifted from a 2% to a 6% decline (California, Illinois, New York, Texas — California driven by the undocumented-immigrant population), with the revenue loss offset by higher Marketplace revenue so premium is unchanged. A May 8 Investor Day was flagged for the 2029 outlook.

Participant coverage from the latest call.

Group	Participants	Count
Management	Operator; Jeffrey Geyer — Head of Investor Relations, Molina Healthcare, Inc.; Joseph Zubretsky — President, CEO & Director, Molina Healthcare, Inc.; Mark Keim — Senior EVP, CFO & Treasurer, Molina Healthcare, Inc.	4
Analysts	Andrew Mok — Director, Barclays Bank PLC, Research Division; Stephen Baxter — Senior Equity Analyst, Wells Fargo Securities, LLC, Research Division; Ann Hynes — Managing Director of Americas Research & Senior Healthcare Services Equity Analyst, Mizuho Securities USA LLC, Research Division; Kevin Fischbeck — Managing Director in Equity Research, BofA Securities, Research Division; Justin Lake — MD & Senior Healthcare Services Analyst, Wolfe Research, LLC; Sarah James — Research Analyst, Cantor Fitzgerald & Co., Research Division; Albert Rice — Health Care Services Analyst, UBS Investment Bank, Research Division; Scott Fidel — Research Analyst, Goldman Sachs Group, Inc., Research Division; John Stansel — Analyst, JPMorgan Chase & Co, Research Division; Erin Wilson Wright — Equity Analyst, Morgan Stanley, Research Division; Ryan Langston — Director & Senior Analyst, TD Cowen, Research Division; Hua Ha — Senior Research Analyst, Robert W. Baird & Co. Incorporated, Research Division; Lance Wilkes — Senior Analyst, Bernstein Institutional Services LLC, Research Division; George Hill — MD & Equity Research Analyst, Deutsche Bank AG, Research Division; Jason Cassorla — VP & Equity Research Analyst, Guggenheim Securities, LLC, Research Division	15

Curated latest-call exchanges; one row per analyst topic.

Analyst	Firm	Topic	What changed in Q&A
Andrew Mok	Barclays	Higher Medicaid attrition	Pressed which states drive the incremental membership pressure; management named California, Illinois, New York and Texas, with California tied to the undocumented-immigrant population, and argued no associated acuity shift.
Stephen Baxter	Wells Fargo	Acuity-shift assumption	Questioned whether zero further acuity shift is a reasonable baseline given how tightly enrollment is now managed; management pointed to low/no-utilizers at their lowest recorded level and stayer/leaver ratios near portfolio average.
Kevin Fischbeck	BofA Securities	Why guidance not raised	Asked whether holding guidance is routine Q1 caution or reflects real unquantifiable unknowns; management said the indicators are positive but a two-quarter, time-tested base is prudent after 2025's volatility.
Justin Lake	Wolfe Research	Medicaid trend composition	Sought quarterly trend figures and the acuity-versus-core split by cost category; management gave pure-period color but declined a clean quarterly breakout, citing seasonality and noise.
Scott Fidel	Goldman Sachs	Medicare duals vs. exiting MAPD	Asked to parse continuing duals MCR from the MAPD book being exited; management framed the 2027 duals-only structure and cited a ~$5.5 billion, ~94% MLR run rate.
Michael Ha	Baird	Low/no-utilizer definition	Pushed for the MLR buckets that define low utilizers; management declined to disclose the definition or absolute numbers, saying the directional decline holds across every definition tested.
George Hill	Deutsche Bank	2027 work requirements	Asked how states will administer community-engagement/work requirements; management cited early-mover insight from Nebraska but flagged that CMS guidance on ex-parte and medical-frailty rules remains unclear.

Theme tracker

Themes are curator-classified across supplied calls.

Theme	Status	Quarters mentioned	Read-through
Medicaid rate/trend imbalance and market underfunding	persisted	Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	The central margin debate. Framing hardened from 2023-early-2024's "actuarially sound" rates to a recurring claim that the managed-Medicaid market is 300-400 bps underfunded, with Molina positioned as best-in-class within it. Each 100 bps of Medicaid MCR is repeatedly tied to roughly $4.50-$5 of EPS, making rate restoration the key swing factor.
Redetermination acuity shift and low/no-utilizer analysis	persisted	Q2 2023, Q3 2023, Q4 2023, Q1 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	Present every quarter but the tone inverted: "negligible" in 2023, a ~250 bps drag on 2025 trend, and now argued to be "largely behind us." The low/no-utilizer statistic and stayer/leaver analysis became the core evidentiary prop across the two most recent calls.
Marketplace de-risking and exposure reduction	emerged	Q2 2025, Q3 2025, Q4 2025, Q1 2026	Emerged mid-2025 as enhanced-subsidy expiration and risk-pool volatility drove a ~30% average repricing, a ~20% county-footprint cut and a planned ~50% premium decline. A clear strategic reversal from the prior posture.
Marketplace as a growth engine funded by reinvested excess margin	dropped	Q4 2023, Q1 2024, Q2 2024, Q4 2024, Q1 2025	Through early 2025 Molina touted two years of sub-target Marketplace MCRs (~75%) and reinvested "excess margin" to grow ~60%. That growth narrative disappeared as the segment pivoted to deliberate shrinkage — the dropped framing is itself signal about the risk pool.
Risk-corridor protection as a margin buffer	dropped	Q2 2023, Q3 2023, Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024	Corridors (~200 bps of protection) were a frequent talking point through 2024. By Q3 2025 protection was "very limited," and recent calls barely mention it — the cushion that muted early trend pressure has effectively lapsed from the story.
Medicare pivot to integrated duals (MMP to FIDE/HIDE) and MAPD exit	emerged	Q3 2024, Q4 2024, Q1 2025, Q3 2025, Q4 2025, Q1 2026	The duals-integration transition built through 2024-2025 and crystallized into a decision to exit traditional MAPD for 2027, cited as a ~$1 EPS drag in 2026 that reverses. Positions Medicare as a duals-only franchise aligned with Medicaid integration.
Embedded earnings as forward value marker	persisted	Q2 2023, Q3 2023, Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026	A fixture every call, growing from ~$4 to greater than $11 per share as RFP wins (Georgia, Texas, the $6bn Florida CMS contract) and acquisitions accumulated. Management leans on it to argue current depressed EPS understates franchise value.

Guidance ledger

Quotes, calls, and speakers are source-verified; outcomes are curator-classified.

Verbatim guidance	Call	Speaker	Curator outcome	Outcome note
“We project 2025 premium revenue of approximately $42 billion and adjusted earnings per share of at least $24.50”	Molina Healthcare, Inc., Q4 2024 Earnings Call, Feb 06, 2025 · 2025-02-06T13:00:00	Joseph Zubretsky	missed	Full-year 2025 adjusted EPS ultimately came in at $11.03, less than half this initial guide, on 2025's Medicaid, Medicare and Marketplace trend pressure.
“Our full year 2025 adjusted earnings per share guidance is now expected to be approximately $14 per share”	Molina Healthcare, Inc., Q3 2025 Earnings Call, Oct 23, 2025 · 2025-10-23T12:00:00	Joseph Zubretsky	missed	This mid-year cut (from a prior $19) still proved optimistic; the Q4 retro items in California and continued trend pressure took actual FY2025 adjusted EPS to $11.03.
“we are well on our way to meeting our target of $46 billion of premium revenue in 2026 and at least $52 billion in 2027”	Molina Healthcare, Inc., Q4 2024 Earnings Call, Feb 06, 2025 · 2025-02-06T13:00:00	Joseph Zubretsky	missed	The $46 billion 2026 revenue target was withdrawn; 2026 premium is now guided to approximately $42 billion, chiefly on the planned Marketplace reduction and Georgia/Texas contracts slipping to 2027.
“Our 2026 adjusted earnings per share guidance is at least $5.”	Molina Healthcare, Inc., Q4 2025 Earnings Call, Feb 06, 2026 · 2026-02-06T13:00:00	Joseph Zubretsky	pending	Reaffirmed on the Q1 2026 call despite a modestly favorable first quarter; management is holding rather than raising pending second-quarter results.
“In Medicaid, the full year MCR of 92.9% includes rate increases of 4% and medical cost trend at 5%.”	Molina Healthcare, Inc., Q1 2026 Earnings Call, Apr 23, 2026 · 2026-04-23T12:00:00	Mark Keim	pending	Q1 2026 Medicaid ran a 92% MCR with trend modestly favorable, and management said Q1 annualized trend would land below 5%; the full-year outcome is not yet determinable.

Q&A pressure map

Question counts and firms are curator tallies; analyst coverage shown above.

Topic	Questions	Firms	Pressure / response
Acuity-shift risk and the low/no-utilizer assumption	4	Barclays, Wells Fargo, Baird, Deutsche Bank	The hardest-pressed topic on the latest call and a recurring one across 2025. Analysts repeatedly tested whether "no further acuity shift" holds now that enrollment is tightly managed. Management leaned on stayer/leaver data and the low/no-utilizer statistic but declined to disclose its definition or the underlying numbers, a non-disclosure worth flagging even though the thrust of each question was addressed.
Refusal to raise guidance after a favorable quarter	3	BofA Securities, Morgan Stanley, UBS	Analysts pushed on whether the caution signals specific unknowns; management consistently answered that nothing unusual occurred in Q1 and that a two-quarter, "time tested" base is simply prudent after 2025's volatility.
Medicaid cost-trend composition and cadence	2	Wolfe Research, Bernstein	Requests for quarterly trend figures and an acuity-versus-core split were met with pure-period color rather than a clean quarterly breakout, which management declined citing seasonality and noise.
Medicare duals economics ahead of the MAPD exit	2	Goldman Sachs, TD Cowen	Analysts sought run-rate visibility on the continuing duals book separate from the MAPD product being exited for 2027, and an update on efforts to transfer rather than wind down MAPD.

Language shifts

Only language evidence verified against the referenced component is shown.

Observation	Verbatim evidence	Call ID	Component
Baseline confidence before the deterioration: in early 2025 management framed long-term targets as firmly achievable, language that later gave way to loss-quarter caveats.	“remain very confident in our ability to achieve the long-term targets that we shared with you at our November Investor Day”	1914754214	2
New risk vocabulary entered the script as full-year 2025 results fell to an adjusted loss quarter — 2025 trend recast as an outlier rather than a new normal.	“We believe the medical cost trend in 2025 was an aberration, an anomaly by historical standards.”	1975844137	2
Introduction of explicit "trough" framing, positioning 2026 as the bottom of the Medicaid margin cycle rather than a further step down.	“We believe our 2026 forecast for Medicaid is the trough for managed Medicaid margins.”	1975844137	2
Even after a favorable quarter, prudence dominates over renewed confidence; guidance is treated as data-gated, echoing the repeated "time tested" refrain.	“merely reaffirming our prior full year guidance is a prudent approach at this early point in the year and in this current environment.”	1986884066	2

The call history sets up a clean question. Management's thesis is that 2025's margin collapse was driven by a redetermination acuity shift that is now spent and by Medicaid rates that states will restore; Q1 2026 delivered the first data consistent with that. Unresolved is whether states close the claimed 300-400 bps of underfunding fast enough — and management's own refusal to raise guidance after a good quarter signals they want more proof too. The May 8 Investor Day and second-quarter results are the near-term arbiters.